These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
159 related articles for article (PubMed ID: 35784548)
1. Risk Factors for Neck Nodal Metastasis in Papillary Thyroid Cancer With BRAF V600E Mutation. Han Y; Hou L; Zhao B; Gao L; Li S Front Endocrinol (Lausanne); 2022; 13():884428. PubMed ID: 35784548 [TBL] [Abstract][Full Text] [Related]
4. Conventional Ultrasound, Immunohistochemical Factors and BRAF Chen J; Li XL; Zhao CK; Wang D; Wang Q; Li MX; Wei Q; Ji G; Xu HX Ultrasound Med Biol; 2018 Nov; 44(11):2296-2306. PubMed ID: 30100099 [TBL] [Abstract][Full Text] [Related]
5. Predictive Value of BRAF Song JY; Sun SR; Dong F; Huang T; Wu B; Zhou J Curr Med Sci; 2018 Oct; 38(5):785-797. PubMed ID: 30341513 [TBL] [Abstract][Full Text] [Related]
6. Risk and Prognostic Factors for BRAF Wei X; Wang X; Xiong J; Li C; Liao Y; Zhu Y; Mao J Biomed Res Int; 2022; 2022():9959649. PubMed ID: 35647194 [TBL] [Abstract][Full Text] [Related]
7. [Study on the correlation between BRAF(V600E) mutation and lymphatic metastases in papillary thyroid cancer staged preoperativelv as N0]. Gao Q; Zhang W; Wang N; Duan H; Zhou Y; Zhang W; Zhao D Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2015 Dec; 29(23):2048-52. PubMed ID: 27101676 [TBL] [Abstract][Full Text] [Related]
8. A meta-analysis evaluating the relationship between B-type Raf kinase mutation and cervical lymphatic metastasis in papillary thyroid cancer. Ma H; Wang R; Fang J; Zhong Q; Chen X; Hou L; Feng L; Chen X; Huang Z; Zhao H Medicine (Baltimore); 2020 Jan; 99(5):e18917. PubMed ID: 32000400 [TBL] [Abstract][Full Text] [Related]
9. Correlation between US-FNAC with BRAF V600E Mutation Analysis and Central Neck Lymph Node Metastasis in cN0 Papillary Thyroid Cancer. Li R; Hao J; Zhu Z; Qiao X; Wang L; Zhou Z Biomed Res Int; 2021; 2021():9937742. PubMed ID: 34307677 [TBL] [Abstract][Full Text] [Related]
10. The synergic effect of BRAF Qu HJ; Qu XY; Hu Z; Lin Y; Wang JR; Zheng CF; Tan Z Endocr J; 2018 Jan; 65(1):113-120. PubMed ID: 29070763 [TBL] [Abstract][Full Text] [Related]
11. Clinicopathological characteristics including BRAF V600E mutation status and PET/CT findings in papillary thyroid carcinoma. Choi EK; Chong A; Ha JM; Jung CK; O JH; Kim SH Clin Endocrinol (Oxf); 2017 Jul; 87(1):73-79. PubMed ID: 28329426 [TBL] [Abstract][Full Text] [Related]
12. BRAF Shi C; Cao J; Shi T; Liang M; Ding C; Lv Y; Zhang W; Li C; Gao W; Wu G; Man J World J Surg Oncol; 2020 Jun; 18(1):145. PubMed ID: 32593310 [TBL] [Abstract][Full Text] [Related]
13. Association between diffuse lymphocytic infiltration and papillary thyroid cancer aggressiveness according to the presence of thyroid peroxidase antibody and BRAF Lee YK; Park KH; Park SH; Kim KJ; Shin DY; Nam KH; Chung WY; Lee EJ Head Neck; 2018 Oct; 40(10):2271-2279. PubMed ID: 29935011 [TBL] [Abstract][Full Text] [Related]
14. Relevance and clinicopathologic relationship of BRAF V600E, TERT and NRAS mutations for papillary thyroid carcinoma patients in Northwest China. Huang M; Yan C; Xiao J; Wang T; Ling R Diagn Pathol; 2019 Jul; 14(1):74. PubMed ID: 31300059 [TBL] [Abstract][Full Text] [Related]
15. Associations of the BRAF V600E Mutation and PAQR3 Protein Expression with Papillary Thyroid Carcinoma Clinicopathological Features. Gao J; Ma XP; Deng FS; Jiang L; Jia WD; Li M Pathol Oncol Res; 2020 Jul; 26(3):1833-1841. PubMed ID: 31758408 [TBL] [Abstract][Full Text] [Related]
16. Predicting factors of central lymph node metastasis and BRAF Zhou SL; Guo YP; Zhang L; Deng T; Xu ZG; Ding C; Sun WC; Zhao YW; Kong LF World J Surg Oncol; 2021 Jul; 19(1):211. PubMed ID: 34256769 [TBL] [Abstract][Full Text] [Related]
17. Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer. Xing M; Alzahrani AS; Carson KA; Viola D; Elisei R; Bendlova B; Yip L; Mian C; Vianello F; Tuttle RM; Robenshtok E; Fagin JA; Puxeddu E; Fugazzola L; Czarniecka A; Jarzab B; O'Neill CJ; Sywak MS; Lam AK; Riesco-Eizaguirre G; Santisteban P; Nakayama H; Tufano RP; Pai SI; Zeiger MA; Westra WH; Clark DP; Clifton-Bligh R; Sidransky D; Ladenson PW; Sykorova V JAMA; 2013 Apr; 309(14):1493-501. PubMed ID: 23571588 [TBL] [Abstract][Full Text] [Related]
18. Association between BRAF V600E mutation and regional lymph node metastasis in papillary thyroid carcinoma. Lu J; Gao J; Zhang J; Sun J; Wu H; Shi X; Teng L; Liang Z Int J Clin Exp Pathol; 2015; 8(1):793-9. PubMed ID: 25755776 [TBL] [Abstract][Full Text] [Related]
19. BRAF V600E mutation is associated with tumor aggressiveness in papillary thyroid cancer. Kim SJ; Lee KE; Myong JP; Park JH; Jeon YK; Min HS; Park SY; Jung KC; Koo do H; Youn YK World J Surg; 2012 Feb; 36(2):310-7. PubMed ID: 22190222 [TBL] [Abstract][Full Text] [Related]
20. BRAF and KRAS mutations in papillary thyroid carcinoma in the United Arab Emirates. Al-Salam S; Sharma C; Afandi B; Al Dahmani K; Al-Zahrani AS; Al Shamsi A; Al Kaabi J PLoS One; 2020; 15(4):e0231341. PubMed ID: 32315324 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]